IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IDYA IDEAYA Biosciences

盘前交易 08-06 06:30:47 EDT

36.04

-0.07

-0.19%

盘前36.02

-0.02-0.06%

06:22 EDT

最高36.97	最低35.78	成交量100.49万
今开36.27	昨收36.11	日振幅3.29%
总市值34.70亿	流通市值34.47亿	总股本9,627万
成交额3,643万	换手率1.05%	流通股本9,564万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IDYA","market":"US","secType":"STK","nameCN":"IDEAYA Biosciences","latestPrice":36.04,"timestamp":1785960000000,"preClose":36.11,"halted":0,"volume":1004923,"hourTrading":{"tag":"盘前","latestPrice":36.02,"preClose":36.04,"latestTime":"06:22 EDT","volume":100,"amount":3602.0000000000005,"timestamp":1786011720841,"change":-0.02,"changeRate":-0.000555,"amplitude":0},"delay":0,"changeRate":-0.001938521185267247,"floatShares":95636532,"shares":96274800,"eps":-1.956123,"marketStatus":"盘前交易","change":-0.07,"latestTime":"08-06 06:30:47 EDT","open":36.27,"high":36.97,"low":35.7812,"amount":36425634.916370004,"amplitude":0.032922,"askPrice":39.88,"askSize":100,"bidPrice":32.79,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.956123,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786023000000},"marketStatusCode":1,"adr":0,"listingDate":1558584000000,"exchange":"NASDAQ","adjPreClose":36.04,"preHourTrading":{"tag":"盘前","latestPrice":36.02,"preClose":36.04,"latestTime":"06:22 EDT","volume":100,"amount":3602.0000000000005,"timestamp":1786011720841,"change":-0.02,"changeRate":-0.000555,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":36.04,"preClose":36.04,"latestTime":"19:34 EDT","volume":91627,"amount":3302237.2,"timestamp":1785972847519,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3011609058134084,"impliedVol":0.4009,"impliedVolPercentile":0.104},"requestUrl":"/m/hq/s/IDYA","defaultTab":"news","newsList":[{"id":"1169026792","title":"IDEAYA Biosciences宣布IDE892——有望成为同类最佳MTA协同PRMT5抑制剂——启动MTAP缺失胰腺癌和肺癌1/2期研究第二部分单药扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1169026792","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169026792?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:01","pubTimestamp":1785146471,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences今日正式宣布，其候选药物IDE892——一种被视作具有“同类最佳”潜力的MTA协同PRMT5抑制剂——已启动1/2期临床研究的第二部分单药扩展阶段。该研究聚焦于MTAP基因缺失的胰腺癌和肺癌患者。此次启动的单药扩展部分，将在一系列经过严格筛选的MTAP缺失肿瘤患者中，进一步评估IDE892的安全性、耐受性及初步抗肿瘤活性。IDEAYA公司表示，基于前期临床数据，IDE892展现出令人鼓舞的潜力，有望改变当前MTAP缺失癌症的治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193372500","title":"IDEAYA Biosciences 宣布拟进行高达3亿美元的普通股及预融资权证公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1193372500","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193372500?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:02","pubTimestamp":1780948937,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences 宣布，公司计划进行一项公开发行，预计募集资金总额最高可达3亿美元。此次发行将包含公司普通股以及与之配套的预融资权证。\n此举旨在为公司后续的研发活动及一般运营提供资金支持。具体的发行条款，包括发行的股票数量、权证条款及最终定价，将根据市场状况及其他因素最终确定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102086458","title":"IDEAYA Biosciences宣布与罗氏在MTAP缺失型RAS突变胰腺癌领域达成临床合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1102086458","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102086458?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:00","pubTimestamp":1780480823,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布，已与罗氏就针对MTAP缺失型RAS突变胰腺癌的联合疗法开发达成临床合作。此项合作旨在探索IDEAYA的靶向疗法与罗氏的相关疗法相结合，为这一难治性癌症亚型患者开发新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103177449","title":"IDEAYA Biosciences公布截至2026年3月31日持有约9.73亿美元现金及证券 资金可支撑运营至2030年","url":"https://stock-news.laohu8.com/highlight/detail?id=1103177449","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103177449?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:17","pubTimestamp":1777976237,"startTime":"0","endTime":"0","summary":"生物科技公司IDEAYA Biosciences（股票代码：IDYA）最新财务数据显示，截至2026年3月31日，公司持有的现金及证券总额约为9.73亿美元。这一资金规模足以支持公司运营至2030年，资金续航时间与先前预期保持一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168624894","title":"IDEAYA Biosciences将于五月启动RTOR申请，新药上市申请预计2026年下半年完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1168624894","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168624894?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:11","pubTimestamp":1777543916,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布，公司计划于今年五月启动实时肿瘤学审评（RTOR）提交程序。这一重要举措标志着其候选药物开发进入关键阶段。\n根据最新时间表，IDEAYA Biosciences预计将在2026年下半年完成新药上市申请（NDA）的提交工作。该时间节点的确立为后续商业化进程奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179626267","title":"IDEAYA Biosciences飙涨逾40%！因眼癌药物组合试验达到主要目标并计划提交新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1179626267","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179626267?lang=zh_cn&edition=full","pubTime":"2026-04-13 18:38","pubTimestamp":1776076736,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences今日盘前股价大幅上涨31.15%，引起了市场的广泛关注。独立中心影像评估确认，该组合疗法在主要疗效指标——中位无进展生存期方面展现出具有统计学意义的显著改善。具体数据显示，联合治疗组的中位生存期提高了6.9个月，而对照组仅为3.1个月，并且观察到了完全缓解病例。基于这些积极数据，公司计划在2026年下半年向美国食品药品监督管理局提交新药申请，寻求加速批准路径。","market":"sg","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"IDEAYA Biosciences飙涨逾40%！因眼癌药物组合试验达到主要目标并计划提交新药申请","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178706059","title":"IDEAYA与施维雅公布Darovasertib联合克唑替尼一线治疗HLA-A*02:01阴性转移性葡萄膜黑色素瘤的2/3期注册试验（OPTIMUM-02）积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1178706059","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178706059?lang=zh_cn&edition=full","pubTime":"2026-04-13 18:07","pubTimestamp":1776074841,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences与施维雅联合宣布，其针对Darovasertib与克唑替尼组合疗法用于一线治疗HLA-A*02:01阴性转移性葡萄膜黑色素瘤的2/3期注册临床试验（OPTIMUM-02）取得积极顶线结果。该突破性进展标志着转移性葡萄膜黑色素瘤治疗领域迈出关键一步，为缺乏HLA-A*02:01基因型的患者群体提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175431474","title":"IDEAYA Biosciences临床试验达到主要终点 BICR评估显示中位无进展生存期实现统计学显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1175431474","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175431474?lang=zh_cn&edition=full","pubTime":"2026-04-13 18:01","pubTimestamp":1776074474,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布其临床试验成功达到主要研究终点。经独立中心影像评估确认，该研究在主要疗效指标——中位无进展生存期方面展现出具有统计学意义的显著改善。\n这一突破性进展标志着公司在靶向疗法开发领域取得重要里程碑，为后续临床开发计划的推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119778358","title":"IDEAYA Biosciences将于2026年4月13日公布转移性葡萄膜黑色素瘤II/III期Optimum-02试验顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1119778358","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119778358?lang=zh_cn&edition=full","pubTime":"2026-04-11 04:06","pubTimestamp":1775851578,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布，公司计划于2026年4月13日（星期一）正式公布其针对转移性葡萄膜黑色素瘤的II/III期Optimum-02临床试验的顶线结果。这一关键数据的披露备受业界关注，或将直接影响公司未来研发策略与市场布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148847126","title":"IDEAYA Biosciences与阿斯利康达成临床合作 共同推进IDE849联合Imfinzi治疗小细胞肺癌研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1148847126","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148847126?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:24","pubTimestamp":1775730286,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences Inc于2026年4月8日宣布与阿斯利康制药达成临床合作协定。根据美国证券交易委员会披露文件，双方将针对IDEAYA研发的IDE849与阿斯利康的Imfinzi联合疗法，开展针对广泛期小细胞肺癌的临床评估。根据协议安排，IDEAYA将作为临床试验的申办方，主导研究推进；阿斯利康则负责提供其抗PD-L1抗体Imfinzi。此次与阿斯利康的强强联合，有望加速该药物在难治性肿瘤领域的开发进程。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1481600234.SGD","LU0963555726.SGD","LU1051770623.HKD","SG9999013999.USD","LU2089284900.SGD","LU1481599808.USD","LU1019632923.USD","LU1196032939.SGD","LU2125909247.SGD","LU2355687059.USD","IE00BFTCPJ56.SGD","LU0823399737.USD","LU0029864427.USD","LU0784383803.USD","LU0887340254.USD","LU2125909593.SGD","AZN.UK","03165","LU0345777659.USD","LU0158827948.USD","LU1061106388.HKD","LU0211326839.USD","LU1989772840.SGD","LU1291159041.SGD","LU0957799991.USD","LU1496350171.SGD","LU0011850046.USD","LU1119994496.HKD","LU1267930573.SGD","LU1814569148.SGD","LU0171293334.USD","LU0792757196.USD","LU0128525929.USD","LU1261432733.SGD","LU0496365809.HKD","LU0266013472.USD","LU2433249047.HKD","LU0203345920.USD","LU0128525689.USD","LU0052756011.USD","LU1078025761.USD","LU1323610961.USD","LU0203347892.USD","LU1989771016.USD","LU0077335932.USD","LU0047473722.EUR","LU0889565080.SGD","LU0058720904.USD","LU0114720955.EUR","LU1023059063.AUD","LU0964806797.USD","LU2108987350.USD","LU1153585028.USD","IE00BKPKM643.USD","LU1046234339.USD","LU2133065610.SGD","LU1983299246.USD","LU0757432116.USD","LU2114397693.USD","LU1923622614.USD","LU0784385840.USD","LU1989772923.USD","LU0960981461.USD","LU1880407132.USD","LU0857590862.USD","LU0972486137.USD","LU0949170772.SGD","LU1267930813.SGD","IE0034235188.USD","IE00B2B36J28.USD","LU0432979614.USD","LU0211327993.USD","LU1019634622.SGD","LU2293690082.USD","IE00BJJMRZ35.SGD","LU2089283258.USD","LU1170363599.USD","LU0345777147.USD","LU0310800965.SGD","LU1267930227.SGD","IE00B3T34201.USD","LU1267930490.SGD","LU2023251221.USD","LU0738911758.USD","LU0310799852.SGD","LU0784384876.USD","LU0575583348.USD","IE00B4R5TH58.HKD","LU0553294199.USD","LU1015430645.USD","LU1064927863.SGD","LU2091194634.USD","LU2468319806.SGD","LU0211326755.USD","LU1003076772.USD","LU0526926950.USD","LU0640478417.SGD","LU0047473722.SGD","LU1880407215.USD","BK4139","LU2293690249.USD","LU0997586515.USD","LU1301847155.USD","LU0784385170.HKD","LU0976567544.SGD","LU2279689827.SGD","LU1153584641.USD","LU1057294990.SGD","LU0545039389.USD","IE0009355771.USD","BK5011","LU0310800379.SGD","SGXZ57979304.SGD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU0949170426.SGD","LU0708994859.HKD","LU0661504455.SGD","LU1104425308.USD","LU1273509221.SGD","LU0882574055.USD","LU0889566641.SGD","LU0499090636.EUR","LU0920783379.SGD","LU1084165304.USD","LU0920840948.USD","LU0997586432.USD","LU2089984988.USD","IDYA","LU2324357040.USD","SG9999001176.SGD","LU1496350502.SGD","LU0827474353.SGD","IE0002141913.USD","LU0122379950.USD","LU0211328371.USD","LU2539964713.USD","LU0823416689.USD","SG9999001176.USD","LU0557290698.USD","LU1487256676.USD","LU2112291526.USD","LU1003077747.HKD","LU0969580561.USD","LU0390134368.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166712162","title":"IDEAYA Biosciences推进Ide849针对Dll3上调实体瘤的全球一期临床试验——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1166712162","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166712162?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:07","pubTimestamp":1775729236,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences公司正在积极推进其候选药物Ide849针对Dll3上调实体瘤的全球一期临床试验。这一研发进展已通过美国证券交易委员会的文件正式披露。该试验旨在评估Ide849在Dll3表达上调的各类实体瘤患者中的安全性、耐受性及初步疗效。此次全球一期临床试验的推进，标志着IDEAYA Biosciences在精准肿瘤学领域的研究取得重要阶段性成果。公司将继续依托其深厚的靶向治疗研发平台，探索Ide849为特定患者群体提供新的治疗选择的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174843416","title":"IDEAYA Biosciences 达成协议 评估Ide849联合Imfinzi治疗广泛期小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1174843416","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174843416?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:07","pubTimestamp":1775729235,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences公司宣布，已签署一项临床合作协议，旨在评估其研发的候选药物Ide849与阿斯利康的Imfinzi（度伐利尤单抗）联合疗法，用于治疗广泛期小细胞肺癌（ES-SCLC）患者。\n该研究将探索这种联合疗法的安全性、耐受性及初步疗效，为后续的临床开发提供关键数据依据。广泛期小细胞肺癌是一种侵袭性强、治疗选择有限的恶性肿瘤，此项合作有望为该患者群体带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105775904","title":"IDEAYA Biosciences宣布启动Ide574一期临床试验首例患者给药，该潜在首创双效抑制剂靶向乳腺癌、前列腺癌、结直肠癌及肺癌等多类实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1105775904","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105775904?lang=zh_cn&edition=full","pubTime":"2026-04-06 18:01","pubTimestamp":1775469715,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布，其潜在首创双效抑制剂Ide574针对Kat6/7靶点的一期临床试验已完成首例患者给药。该药物旨在治疗包括乳腺癌、前列腺癌、结直肠癌和肺癌在内的多种实体瘤适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148901427","title":"IDEAYA Biosciences宣布启动Ide849与Ide161联合疗法1期临床试验首位患者入组，针对Dll3上调实体瘤适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1148901427","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148901427?lang=zh_cn&edition=full","pubTime":"2026-03-30 18:03","pubTimestamp":1774865026,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences今日宣布，其针对Dll3上调实体瘤适应症的1期联合疗法临床试验已完成首位患者入组。该研究将评估Ide849（一种靶向Dll3的Top1抗体偶联药物）与Ide161（一种PARG抑制剂）的联合用药效果。适应症范围涵盖小细胞肺癌、神经内分泌肿瘤、神经内分泌癌以及黑色素瘤等多种Dll3表达上调的实体瘤类型。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121250878","title":"IDEAYA Biosciences 将举办投资者关系活动并更新 Darovasertib 关键临床数据指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1121250878","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121250878?lang=zh_cn&edition=full","pubTime":"2026-03-22 22:00","pubTimestamp":1774188021,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences 近期宣布了即将举行的投资者关系活动安排，同时披露了其核心产品 Darovasertib 在关键临床试验中的最新数据公布时间表。该公司针对 Darovasertib 的 2/3 期 OPTIMUM-02 试验，更新了关键临床结果的预期发布时间。Darovasertib 作为 IDEAYA 研发管线中的重要资产，其临床进展一直备受业界关注。随着投资者关系活动的临近，公司管理层预计将就研发策略、管线布局及商业化准备等关键议题与市场进行深入沟通。这些动态将为市场提供评估 IDEAYA 未来发展的新视角。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162639065","title":"IDEAYA Biosciences公司计划2026年下半年确定Cdkn2a开发候选药物，2027年上半年提交新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1162639065","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162639065?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:03","pubTimestamp":1773050596,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences公司宣布了其Cdkn2a项目的最新开发时间表。该公司计划在2026年下半年确定开发候选药物，随后在2027年上半年提交新药临床试验申请。这一进展标志着该公司在肿瘤靶向治疗领域的持续推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614511540","title":"IDEAYA生物科学公司开始针对B7H3和PTK7的IDE034一期临床试验，用于晚期实体瘤IDEAYA Biosciences Begins Phase 1 Trial of IDE034 Targeting B7H3 and PTK7 in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2614511540","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2614511540?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:07","pubTimestamp":1772021220,"startTime":"0","endTime":"0","summary":"IDE034 is described as a potential first-in-class ADC that incorporates a topoisomerase I inhibitor payload..IDE034被描述为一种潜在的同类首个ADC，它包含拓扑异构酶I抑制剂有效载荷。The Phase 1 trial aims to assess IDE034 in patients with advanced solid tumors. According to the announcement, the drug’s dual-targeting mechanism focuses on B7H3 and PTK7, two proteins associated with tumor growth and progression. This approach seeks to enhance therapeutic precision while minimizing off-target effects.一期试验旨在评估IDE034在晚期实体瘤患者中的效果。根据公告，该药物的双重靶向机制聚焦于B7H3和PTK7，这两种与肿瘤生长和进展相关的蛋白质。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225201021a4c73b9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225201021a4c73b9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191218960","title":"IDEAYA Biosciences宣布启动Ide034一期临床试验首位患者入组，该药物有望成为同类首创B7h3/Ptk7双特异性Top1 ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=1191218960","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191218960?lang=zh_cn&edition=full","pubTime":"2026-02-25 19:06","pubTimestamp":1772017617,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布，其创新药物Ide034的一期临床试验已完成首位患者入组。该候选药物作为靶向B7h3和Ptk7的双特异性拓扑异构酶1（Top1）抗体偶联药物（ADC），具备成为同类首创疗法的潜力。\n此次临床试验的启动标志着IDEAYA在精准肿瘤治疗领域取得重要进展。Ide034独特的作用机制有望为特定癌症患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194916310","title":"IDEAYA Biosciences任命医学博士、哲学博士Theodora (Theo) Ross为首席开发官","url":"https://stock-news.laohu8.com/highlight/detail?id=1194916310","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194916310?lang=zh_cn&edition=full","pubTime":"2026-02-23 19:00","pubTimestamp":1771844413,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布，正式委任医学博士、哲学博士Theodora（Theo）Ross担任公司首席开发官一职。此次任命将进一步加强公司在肿瘤靶向治疗领域的研发领导力，为推进创新疗法管线注入关键专业力量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613724942","title":"IDEAYA生物科学2025财年实现净利润-1.14亿美元，同比增加58.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613724942","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2613724942?lang=zh_cn&edition=full","pubTime":"2026-02-21 00:00","pubTimestamp":1771603232,"startTime":"0","endTime":"0","summary":"2月21日，IDEAYA生物科学公布财报，公告显示公司2025财年净利润为-1.14亿美元，同比增加58.39%；其中营业收入为2.19亿美元，同比增加3028.57%，每股基本收益为-1.28美元。从资产负债表来看，IDEAYA生物科学总负债86.39百万美元，其中短期债务339000.00美元，资产负债比为0.13，流动比率为0.12。机构评级：截至2026年2月21日，当前有17家机构对IDEAYA生物科学目标价做出预测，其中目标均价为50.76美元，其中最低目标价为31.00美元，最高目标价为79.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221000044a4b6dff8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221000044a4b6dff8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IDYA","BK4023","BK4139","PARG"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ideayabio.com","stockEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":-0.0846},{"period":"3month","weight":0.2762},{"period":"6month","weight":0.1203},{"period":"1year","weight":0.4942},{"period":"ytd","weight":0.0425}],"compareEarnings":[{"period":"1week","weight":0.0553},{"period":"1month","weight":0.0246},{"period":"3month","weight":0.0522},{"period":"6month","weight":0.1146},{"period":"1year","weight":0.2258},{"period":"ytd","weight":0.1289}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"IDEAYA Biosciences, Inc.总部位于加利福尼亚州南旧金山，于2015年6月在特拉华州注册成立。该公司是一家专注于肿瘤学的精准医学公司，致力于为使用分子诊断选择的患者群体发现和开发靶向疗法。他们的方法将识别和验证翻译生物标志物的广泛能力与小分子药物发现相结合，以选择最有可能从他们正在开发的靶向治疗中受益的患者群体。他们正在将这些能力应用于多类精准医学，包括直接靶向致癌途径和合成致死性，这代表了一类新兴的精准医学靶点。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.019424},{"month":2,"riseRate":0.571429,"avgChangeRate":-0.055936},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.105822},{"month":4,"riseRate":0.428571,"avgChangeRate":0.062455},{"month":5,"riseRate":0.571429,"avgChangeRate":0.151132},{"month":6,"riseRate":0.75,"avgChangeRate":0.110114},{"month":7,"riseRate":0.5,"avgChangeRate":0.017276},{"month":8,"riseRate":0.375,"avgChangeRate":-0.026499},{"month":9,"riseRate":0.714286,"avgChangeRate":0.113335},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.051627},{"month":11,"riseRate":0.857143,"avgChangeRate":0.118123},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016661}],"exchange":"NASDAQ","name":"IDEAYA Biosciences","nameEN":"IDEAYA Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供IDEAYA Biosciences(IDYA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"IDEAYA Biosciences,IDYA,IDEAYA Biosciences股票,IDEAYA Biosciences股票老虎,IDEAYA Biosciences股票老虎国际,IDEAYA Biosciences行情,IDEAYA Biosciences股票行情,IDEAYA Biosciences股价,IDEAYA Biosciences股市,IDEAYA Biosciences股票价格,IDEAYA Biosciences股票交易,IDEAYA Biosciences股票购买,IDEAYA Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供IDEAYA Biosciences(IDYA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}